San Francisco, California — According to state and local development sources, Genentech plans to invest $1.5 Billion to build out 1,000,000 square feet of new space in San Francisco. The company plans to occupy the new space in San Francisco, on or about October 1, 2027. According to the company website Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for more than 40 years. Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Our transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis. Genentech became a member of the Roche Group in March of 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech Research and Early Development operates as a separate business unit within Roche.

To learn more about Genentech, visit http://www.gene.com/

Company Contact:
Ashley Magargee, Chief Executive Officer
650-225-1000

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.